Acquired PTEN Loss May Mediate Dabrafenib and Trametinib Resistance in BRAF V600E-Mutated Epithelioid Glioblastoma: A Case Report and Literature Review

Epithelioid glioblastoma is a rare and aggressive variant of that common in children young adults. This frequently has BRAF V600E mutation, recent years, this often treated with mitogen-activated protein kinase inhibitors. An 18-year-old female initially presented headaches vomiting. They were diagnosed an epithelioid temozolomide chemoradiotherapy. Upon progression, they had to redo surgery then received dabrafenib trametinib. one last shortly before fatal tumour progression. Retrospective molecular analysis three specimens showed PTEN mutation arose upon first but was not there initially. There no new mutations after initiation The acquired may have conferred resistance case highlights the potential importance early treatment inhibitors high-grade V600E-mutated gliomas, ideally develops targeted therapy.